X4 Pharmaceuticals Announces Positive Phase 3 Results Showing Mavorixafor Reduced the Rate, Severity, and Duration of Infections vs. Placebo in Participants Diagnosed with WHIM Syndrome
~60% reduction in annualized infection rate seen in the mavorixafor arm vs. placebo (p<0.01) >75%…
Pacvue Launches Pacvue Prism, Powering the Industry’s First Agentic Commerce Grid
Shangri-La Group Debuts ‘Dragonbeat’ with Resounding Success, Cross-Industry Collaborations with Local Creators in Art, Fashion, Gastronomy and Music
EE Power Asia 2026 to Spotlight Technologies Driving the Next Era of Electrification